It’s happened to all of us: you find the perfect model for your needs — a bracket, a box, a cable clip, but it only comes in ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback